Israeli - Kiebrania - Ministry of Health

teva pharmaceutical industries ltd, israel - epinephrine - תמיסה להזרקה - epinephrine 1 mg/ml - epinephrine - epinephrine - relief of respiratory distress due to bronchospasm. rapid relief of hypersensitivity reaction to drugs and other allergens.prolongation of the action of infiltration anesthetics. adrenaline may be of value in restoring cardiac rhythm in cardiac arrest.however it is not used in cardiac failure or in hemorrhagic traumatic or cardiogenic shock. treatment of mucosal congestion of hay fever rhinitis and acute sinusitis.relief of bronchial asthmatic paroxysms. symptomatic relief of serum sickness urticaria and angioneurotic edema.open-angle glaucoma. relaxation of uterine musculature and inhibition of uterine contractions. hemostatic agent in syncope due to complete heart block or carotid sinus hypersensitivity and for resuscitation in cardiac arrest following anesthetic accidents.

Israeli - Kiebrania - Ministry of Health

teva pharmaceutical industries ltd, israel - ciprofloxacin as hydrochloride - טבליה - ciprofloxacin as hydrochloride 250 mg - ciprofloxacin - ciprofloxacin - broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens: invasive infections of the external ear. treatment of acute pulmonary exacerbation of cystic fibrosis associated with p. aeruginosa infections in pediatric patients aged 5-17 years.

Israeli - Kiebrania - Ministry of Health

teva pharmaceutical industries ltd, israel - ciprofloxacin as hydrochloride - טבליה - ciprofloxacin as hydrochloride 750 mg - ciprofloxacin - ciprofloxacin - broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens: invasive infections of the external ear. treatment of acute pulmonary exacerbation of cystic fibrosis associated with p. aeruginosa infections in pediatric patients aged 5-17 years.

Israeli - Kiebrania - Ministry of Health

teva pharmaceutical industries ltd, israel - ciprofloxacin as hydrochloride - טבליה - ciprofloxacin as hydrochloride 750 mg - ciprofloxacin - ciprofloxacin - broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens: invasive infections of the external ear. treatment of acute pulmonary exacerbation of cystic fibrosis associated with p. aeruginosa infections in pediatric patients aged 5-17 years.

Israeli - Kiebrania - Ministry of Health

teva pharmaceutical indust.ltd - carvedilol 12.5 mg - tablets - carvedilol - treatment of symptomatic congestive heart failure. carvedilol teva may be used as adjunct to standard therapy, but may also be used in those patients unable to tolerate an ace inhibitor, or those who are not receiving digitalis, hydralazine or nitrate therapy.

Israeli - Kiebrania - Ministry of Health

teva pharmaceutical indust.ltd - benserazide as hydrochloride 50 mg; levodopa 200 mg - capsules - levodopa and decarboxylase inhibitor - for the relief of symptoms associated with parkinson's disease.

Israeli - Kiebrania - Ministry of Health

teva pharmaceutical indust.ltd - benserazide as hydrochloride 50 mg; levodopa 200 mg - capsules - levodopa and decarboxylase inhibitor - for the relief of symptoms associated with parkinson's disease.

Israeli - Kiebrania - Ministry of Health

vitamed pharmaceutical industries ltd - dexchlorpheniramine maleate; pseudoephedrine hydrochloride - סירופ - dexchlorpheniramine maleate 1 mg / 5 ml; pseudoephedrine hydrochloride 25 mg / 5 ml - pseudoephedrine, combinations - pseudoephedrine, combinations - relief of congestion in the respiratory tract due to allergy.

Israeli - Kiebrania - Ministry of Health

teva pharmaceutical industries ltd, israel - omeprazole - קפסולות - omeprazole 20 mg - omeprazole

Israeli - Kiebrania - Ministry of Health

teva pharmaceutical industries ltd, israel - ramipril - טבליה - ramipril 5 mg - ramipril - ramipril - - hypertension - congestive heart failure - reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.